Journal article
A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity
Abstract
There is an urgent need to develop new tuberculosis (TB) vaccines to safely and effectively boost Bacille Calmette-Guérin (BCG)-triggered T cell immunity in humans. AdHu5Ag85A is a recombinant human type 5 adenovirus (AdHu5)-based TB vaccine with demonstrated efficacy in a number of animal species, yet it remains to be translated to human applications. In this phase 1 study, we evaluated the safety and immunogenicity of AdHu5Ag85A in both …
Authors
Smaill F; Jeyanathan M; Smieja M; Medina MF; Thanthrige-Don N; Zganiacz A; Yin C; Heriazon A; Damjanovic D; Puri L
Journal
Science Translational Medicine, Vol. 5, No. 205,
Publisher
American Association for the Advancement of Science (AAAS)
Publication Date
October 2, 2013
DOI
10.1126/scitranslmed.3006843
ISSN
1946-6234